BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

Post-LOE

acetaminophen; butalbital; caffeine; codeine phosphate

PharmaIN

ANDAORALCAPSULE

Approved

Jul 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (acetaminophen; butalbital; caffeine; codeine phosphate) by PharmaIN is butalbital, a barbiturate, is a gaba a receptor agonist and may inhibit excitatory ampa receptors. Approved for the symptom complex of tension (or muscle contraction) headache, alternative treatments are inadequate, other non-opioid analgesic. First approved in 2020.

Drug data last refreshed 18h ago

Mechanism of Action

Butalbital, a barbiturate, is a GABA A receptor agonist and may inhibit excitatory AMPA receptors. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions. Caffeine is a methylxanthine and CNS stimulant. The exact mechanism…

Indications (3)

the symptom complex of tension (or muscle contraction) headache alternative treatments are inadequate

Worked on BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.